Does "death receptor" signaling play a role in tumorigenesis and cancer therapy?

Oncology Research

Volumn 10, Issue 11-12, 1998, Pages 541-550

  Villunger, Andreas ^a   Strasser, Andreas ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Apoptosis; Bcl 2; Cancer; Caspases; Tnf receptor family

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; FAS ANTIGEN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; APOPTOSIS; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; HUMANS; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 0032233488     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (189)

1. Kerr, J. F. R.; Wyllie, A. H.; Currie, A. R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-257; 1972.
2. Tsujimoto, Y.; Finger, L. R.; Yunis, J.; Nowell, P. C.; Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099; 1984.
3. H on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906; 1985.
4. Cleary, M. L.; Smith, S. D.; Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19-28; 1986.
5. Vaux, D. L.; Cory, S.; Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442; 1988.
6. McDonnell, T. J.; Deane, N.; Platt, F. M.; Nuñez, G.; Jaeger, U.; McKearn, J. P.; Korsmeyer, S. J. bcl-2-immunoglobuIin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88; 1989.
7. Sentman, C. L.; Shutter, J. R.; Hockenbery, D.; Kanagawa, O.; Korsmeyer, S. J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytcs. Cell 67:879-888; 1991.
8. Strasser, A.; Whittingham, S.; Vaux, D. L.; Bath, M. L.; Adams, J. M.; Cory, S.; Harris, A. W. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88:8661-8665; 1991.
9. Strasser, A.; Harris, A. W.; Cory, S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67:889-899; 1991.
10. Strasser, A.; Harris, A. W.; Bath, M. L.; Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333; 1990.
11. McDonnell, T. J.; Korsmeyer, S. J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254-256; 1991.
12. Strasser, A.; Harris, A. W.; Cory, S. Eμ-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 8:1-9; 1993.
13. Linette, G. P.; Hess, J. L.; Sentman, C. L.; Korsmeyer, S. J. Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. Blood 86:1255-1260; 1995.
14. Acton, D.; Domen, J.; Jacobs, H.; Vlaar, M.; Korsmeyer, S.; Berns, A. Collaboration of PIM-1 and BCL-2 in lymphomagenesis. Curr. Top. Microbiol. Immunol. 182:293-298; 1992.
15. Strasser, A.; Elefanly, A. G.; Harris, A. W.; Cory, S. Progenitor tumours from Eμ-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 15:3823-3834; 1996.
16. Jäger, R.; Herzer, U.; Schenkel, J.; Weiher, H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced lumorigenesis of the mammary gland in transgenic mice. Oncogene 15:1787-1795; 1997.
17. Strasser, A.; Huang, D. C. S.; Vaux, D. L. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim. Biophys. Acta 1333:F151-F178; 1997.
18. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88:323-331; 1997.
19. Lowe, S. W.; Schmitt, E. M.; Smith, S. W.; Osborne, B. A.; Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849; 1993.
20. Clarke, A. R.; Purdie, C. A.; Harrison, D. J.; Morris, R. G.; Bird, C. C.; Hooper, M. L.; Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852; 1993.
21. Clarke, A. R.; Gledhill, S.; Hooper, M. L.; Bird, C. C.; Wyllie, A. H. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following γ-irradiation. Oncogene 9:1767-1773; 1994.
22. Strasser, A.; Harris, A. W.; Jacks, T.; Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339; 1994.
23. Lane, D. P. p53, guardian of the genome. Nature 358:15-16; 1992.
24. Metz, T.; Harris, A. W.; Adams, J. M. Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell 82:29-36; 1995.
25. Bedi, A.; Barber, J. P.; Bedi, G. C.; El-Deiry, S.; Sidransky, D.; Vala, M. S.; Akhtar, A. J.; Hilton, J.; Jones, R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148-1158; 1995.
26. Inaba, T.; Inukai, T.; Yoshihara, T.; Seyschab, H.; Ashmun, R. A.; Canman, C. E.; Laken, S. J.; Kastan, M. B.; Look, A. T. Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 382:541-544; 1996.
27. Ramakrishnan, L.; Rosenberg, N. abl genes. Biochim. Biophys. Acta 989:209-224; 1989.
28. Inaba, T. R.; Roberts, W. M.; Shapiro, L. H.; Jolly, K. W.; Raimondi, S. C.; Smith, S. D.; Look, A. T. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 257:531-534; 1992.
29. Hunger, S. P.; Ohyashiki, K.; Toyama, K.; Cleary, M. L. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 6:1608-1620; 1992.
30. Miyashita, T.; Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:5407-5411; 1992.
31. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967; 1993.
32. Li, F.; Ambrosini, G.; Chu, E. Y.; Plescia, J.; Tognin, S.; Marchisio, P. C.; Alten, D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584; 1998.
33. Boise, L. H.; Gonzalez-Garcia, M.; Postema, C. E.; Ding, L.; Lindsten, T.; Turka, L. A.; Mao, X.; Nu«ez, G.; Thompson, C. B. bcl-x, a bcl-2-reIated gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608; 1993.
34. Gibson, L.; Holmgreen, S.; Huang, D. C. S.; Bernard, O.; Copeland, N. G.; Jenkins, N. A.; Sutherland, G. R.; Baker, E.; Adams, J. M.; Cory, S. bcl-w, a novel member of the bcl-1 family, promotes cell survival. Oncogene 13:665-675; 1996.
35. Lin, E. Y.; Orlofsky, A.; Wang, H.-G.; Reed, J. C.; Prystowsky, M. B. A1, a bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood 87:983-992; 1996.
36. Zhou, P.; Qian, L.; Bieszczad, C. K.; Noelle, R.; Binder, M.; Levy, N. B.; Craig, R. W. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92:3226-3239; 1998.
37. Vaux, D. L.; Strasser, A. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 93:2239-2244; 1996.
38. Yuan, J.; Shaham, S.; Ledoux, S.; Ellis, H. M.; Horvitz, H. R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 75:641-652; 1993.
39. Hay, B. A.; Wolff, T.; Rubin, G. M. Expression of baculovirus p35 prevents cell death in Drosophila. Development 120:2121-2129; 1994.
40. Sugimoto, A.; Friesen, P. D.; Rothman, J. H. Baculovirus p35 prevents developmentally programmed cell death and rescues a ced-9 mutant in the nematode Caenorhabditis elegans. EMBO J. 13:2023-2028; 1994.
41. Smith, K. G. C.; Strasser, A.; Vaux, D. L. CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmunedisease. EMBO J. 15:5167-5176; 1996.
42. Kuida, K.; Zheng, T. S.; Na, S.; Kuan, C.-Y.; Yang, D.; Karasuyama, H.; Rakic, P.; Flavell, R. A. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384:368-372; 1996.
43. Kuida, K.; Haydar, T. F.; Kuan, C.-Y.; Gu, Y.; Taya, C.; Karasuyama, H.; Su, M. S.-S.; Rakic, P.; Flavell, R. A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94:325-337; 1998.
44. Hakem, R.; Hakem, A.; Duncan, G. S.; Henderson, J. T.; Woo, M.; Soengas, M. S.; Elia, A.; de la Pompa, J. L.; Kagi, D.; Khoo, W.; Potter, J.; Yoshida, R.; Kaufman, S. A.; Lowe, S. W.; Penninger, J. M.; Mak, T. W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94:339-352; 1998.
45. Varfolomeev, E. E.; Schuchmann, M.; Luria, V.; Chiannilkulchai, N.; Beckmann, J. S.; Mett, I. L.; Rebrikov, D.; Brodianski, V. M.; Kemper, O. C.; Kollet, O.; Lapidot, T.; Soffer, D.; Sobe, T.; Avraham, K. B.; Goncharov, T.; Holtmann, H.; Lonai, P.; Wallach, D. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9:267-276; 1998.
46. Nicholson, D. W.; Thornberry, N. A. Caspases: Killer proteases. Trends Biochem. Sci. 22:299-306; 1997.
47. Thornberry, N. A.; Lazebnik, Y. Caspases: Enemies within. Science 281:1312-1316; 1998.
48. Muzio, M.; Stockwell, B. R.; Stennicke, H. R.; Salvesen, G. S.; Dixit, V. M. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273:2926-2930; 1998.
49. Martin, D. A.; Siegel, R. M.; Zheng, L.; Lenardo, M. J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J. Biol. Chem. 273:4345-4349; 1998.
50. Srinivasula, S. M.; Ahmad, M.; Fernandes-Alnemri, T.; Alnemri, E. S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1:949-957; 1998.
51. Yang, X.; Chang, H. Y.; Baltimore, D. Essential role of CED-4 oligomerization in CED-3 activation and apoptosis. Science 281:1355-1357; 1998.
52. Liu, X.; Zou, H.; Slaughter, C.; Wang, X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175-184; 1997.
53. Rudel, T.; Bokoch, G. M. Membrane and morphological changes in apoplotic cells regulated by caspase-mediated activation of PAK2. Science 276:1571-1574; 1997.
54. Enari, M.; Sakahira, H.; Yokoyama, H.; Okawa, K.; Iwamatsu, A.; Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391:43-50; 1998.
55. Yoshida, H.; Kong, Y.-Y.; Yoshida, R.; Elia, A. J.; Hakem, A.; Hakem, R.; Penninger, J. M.; Mak, T. W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94:739-750; 1998.
56. Cecconi, F.; Alvarez-Bolado, G.; Meyer, B. I.; Roth, K. A.; Gruss, P. Apaf-1 (CED-4 homologue) regulates programmed cell death in mammalian development. Cell 94:727-737; 1998.
57. Newton, K.; Harris, A. W.; Bath, M. L.; Smith, K. G. C.; Strasser, A. A dominant interfering mutant of FADD/Mort1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17:706-718; 1998.
58. Yeh, W. C.; Pompa, J. L.; McCurrach,. M. E.; Shu, H. B.; Elia, A. J.; Shahinian, A.; Ng, M.; Wakeham, A.; Khoo, W.; Mitchell, K.; El-Deiry, W. S.; Lowe, S. W.; Goeddel, D. V.; Mak, T. W. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-1958; 1998.
59. Zhang, J.; Cado, D.; Chen, A.; Kabra, N. H.; Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mortl. Nature 392:296-299; 1998.
60. Strasser, A.; Harris, A. W.; Huang, D. C. S.; Krammer, P. H.; Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14:6136-6147; 1995.
61. Memon, S. A.; Moreno, M. B.; Petrak, D.; Zacharchuk, C. M. Bcl-2 blocks glucocorticoid-but not Fas- or activation-induced apoptosis in a T cell hybridoma, J. Immunol. 115:4644-4652; 1995.
62. L and adenovirus protein ElB19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14:405-4114; 1997.
63. L, and Apaf-1 form a ternary complex. J. Biol. Chem. 273:5841-5845; 1998.
64. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA 95:4386-4391; 1998.
65. Hsu, H.; Shu, H.-B.; Pan, M.-G.; Goeddel, D. V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308; 1996.
66. Li, H.; Zhu, H.; Xu, C.-J.; Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501; 1998.
67. Luo, X.; Budlhardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-190; 1998.
68. Kozopas, K. M.; Yang, T.; Buchan, H. L.; Zhou, P.; Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2. Proc. Natl. Acad. Sci. USA 90:3516-3520; 1993.
69. Song, Q.; Kuang, Y.; Dixit, V. M.; Vincenz, C. Boo, a novel negative regulator of cell death, interacts with Apaf-1. EMBO J. 18:167-178; 1999.
70. Oltvai, Z. N.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619; 1993.
71. Farrow, S. N.; White, J. H. M.; Martinou, I.; Raven, T.; Pun, K.-T.; Grinham, C. J.; Martinou, J.-C.; Brown, R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374:731-733; 1995.
72. Chittenden, T.; Harrington, E. A.; O'Connor, R.; Flemington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:733-736; 1995.
73. Kiefer, M. C.; Brauer, M. J.; Powers, V. C.; Wu, J. J.; Umansky, S. R.; Tomei, L. D.; Barr, P. J. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374:736-739; 1995.
74. Hsu, S. Y.; Kaipia, A.; McGee, E.; Lomeli, M.; Hsueh, A. J. W. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective antiapoptotic Bcl-2 family members. Proc. Natl. Acad. Sci. USA 94:12401-12406; 1997.
75. L and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291; 1995.
76. Boyd, J. M.; Gallo, G. J.; Elangovan, B.; Houghton, A. B.; Malstrom, S.; Avery, B. J.; Ebb, R. G.; Subramanian, T.; Chittenden, T.; Lutz, R. J.; Chinnadurai, G. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11:1921-1928; 1995.
77. Wang, K.; Yin, X.-M.; Chao, D. T.; Milliman, C. L.; Korsmeyer, S. J. BID: A novel BH3 domain-only death agonist. Genes Dev. 10:2859-2869; 1996.
78. O'Connor, L.; Strasser, A.; O'Reilly, L. A.; Hausmann, G.; Adams, J. M.; Cory, S.; Huang, D. C. S. Bim - a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17:384-395; 1998.
79. Hegde, R.; Srinivasula, S. M.; Ahmad, M.; Femandes-Alnemri, T.; Alnemri, E. S. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J. Biol. Chem. 273:7783-7786; 1998.
80. Ellis, H. M.; Horvitz, H. R. Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817-829; 1986.
81. Hengartner, M. O.; Ellis, R. E.; Horvitz, H. R. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356:494-499; 1992.
82. Conradt, B.; Horvitz, H. R. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 93:519-529; 1998.
83. Spector, M. S.; Desnoyers, S.; Hoeppner, D. J.; Hengartner, M. O. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 385:653-656; 1997.
84. Chinnaiyan, A. M.; O'Rourke, K.; Lane, B. R.; Dixit, V. M. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 275:1122-1126; 1997.
85. Wu, D. Y.; Wallen, H, D.; Nuñez, G. Interaction and regulation of subcellular localization of Ced-4 by Ced-9. Science 275:1126-1129; 1997.
86. Liu, X.; Kim, C. N.; Yang, J.; Jemmerson, R.; Wang, X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86:147-157; 1996.
87. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E. S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489; 1997.
88. Yang, J.; Liu, X.; Bhalla, K.; Kim, C. N.; Ibrado, A. M.; Cai, J.; Peng, T.-I.; Jones, D. P.; Wang, X. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129-1132; 1997.
89. L as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:6939-6942; 1997.
90. Yang, J.; Liu, X. S.; Bhalla, K.; Kim, C. N.; Ibrado, A. M.; Cai, J. Y.; Peng, T. I.; Jones, D. P.; Wang, X. D. Prevention of apoptosis by Bcl-2 -release of cytochrome c from mitochondria blocked. Science 275:1129-1132; 1997.
91. Hengartner, M. O. Death cycle and Swiss army knives. Nature 391:441-442; 1998.
92. Nagata, S. Apoptosis by death factor. Cell 88:355-365; 1997.
93. Ashkenazi, A.; Dixit, V. M. Death receptors: Signaling and modulation. Science 281:1305-1308; 1998.
94. Wallach, D.; Kovalenko, A. V.; Varfolomeev, E. E.; Boldin, M. P. Death-inducing functions of ligands of the tumor necrosis factor family: A Sanhedrin verdict. Curr. Opin. Immunol. 10:279-288; 1998.
95. Kondo, T.; Suda, T.; Fukuyama, H.; Adachi, M.; Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:409-413; 1997.
96. Schneider, P.; Holler, N.; Bodmer, J. L.; Hahne, M.; Frei, K.; Fontana, A.; Tschopp, J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213; 1998.
97. Strasser, A.; O'Connor, L. Fas ligand - caught between Scylla and Charybdis. Nat. Med. 4:21-22; 1998.
98. Itoh, N.; Nagata, S. A novel protein domain required for apoptosis. J. Biol. Chem. 268:10932-10937; 1993.
99. Tartaglia, L. A.; Ayres, T. M.; Wong, G. H. W.; Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845-853; 1993.
100. Boldin, M. P.; Varfolomeev, E. E.; Pancer, Z.; Mett, I. L.; Camonis, J. H.; Wallach, D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270:7795-7798; 1995.
101. Chinnaiyan, A. M.; O'Rourke, K.; Tewari, M.; Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512; 1995.
102. Hsu, H.; Xiong, J.; Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81:495-504; 1995.
103. Chinnaiyan, A. M.; Tepper, C. G.; Seidin, M. F.; O'Rourke, K.; Kischkel, F. C.; Hellbardt, S.; Krammer, P. H.; Peter, M. E.; Dixit, V. M. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271:4961-4965; 1996.
104. Boldin, M. P.; Goncharov, T. M.; Goltsev, Y. V.; Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 85:803-815; 1996.
105. Muzio, M.; Chinnaiyan, A. M.; Kischkel, F. C.; O'Rourke, K.; Shevchenko, A.; Ni, J.; Scaffidi, C.; Bretz, J. D.; Zhang, M.; Gentz, R.; Mann, M.; Krammer, P. H.; Peter, M. E.; Dixit, V. M. FLICE, a novel FADD homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 85:817-827; 1996.
106. Berlin, J.; Armstrong, R. C.; Ottilie, S.; Martin, D. A.; Wang, Y.; Banks, S.; Wang, G.-H.; Senkevich, T. G.; Alnemri, E. S.; Moss, B.; Lenardo, M. J.; Tomaselli, K. J.; Cohen, J. I. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:1172-1176; 1996.
107. Thome, M.; Schneider, P.; Hofmann, K.; Fickenscher, H.; Meinl, E.; Neipel, F.; Mattmann, C.; Burns, K.; Bodmer, J.-L.; Schroter, M.; Scaffidi, C.; Krammer, P. H.; Peter, M. E.; Tschopp, J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521; 1997.
108. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.-L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-194; 1997.
109. Shu, H.-B.; Halpin, D. R.; Goeddel, D. V. Casper is a FADD-and Caspase-related inducer of apoptosis. Immunity 6:751-763; 1997.
110. Inohara, N.; Koseki, T.; Hu, Y.; Chen, S.; Núñez, G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl. Acad. Sci. USA 94:10717-10722; 1997.
111. Rasper, D. M.; Vaillancourt, J. P.; Hadano, S.; Houtzager, V. M.; Seiden, I.; Keen, S. L. C.; Tawa, P.; Xanthoudakis, S.; Nasir, J.; Martindale, D.; Koop, B. F.; Peterson, E. P.; Thornberry, N. A.; Huang, J. Q.; MacPherson, D. P.; Black, S. C.; Hornung, F.; Lenardo, M. J.; Hayden, M. R.; Roy, S.; Nicholson, D. W. Cell death attentuation by 'Usurpin,' a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ. 5:271-288; 1998.
112. Duan, H.; Dixit, V. M. RAIDD is a new 'death' adaptor molecule. Nature 385:86-89; 1997.
113. Yang, X.; Khosravi-Far, R.; Chang, H. Y.; Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89:1067-1076; 1997.
114. Chang, H. Y.; Nishitoh, H.; Yang, X.; Ichijo, H.; Baltimore, D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein daxx. Science 281:1860-1863; 1998.
115. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C.-P.; Nicholl, J. K.; Sutherland, G. R.; Davis Smith, T.; Rauch, C.; Smith, C. A.; Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682; 1995.
116. Pan, G.; Ni, J.; Wei, Y.-F.; Yu, G.-L.; Gentz, R.; Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818; 1997.
117. Pan, G.; O'Rourke, K.; Chinnaiyan, A. M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113; 1997.
118. Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P.; Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821; 1997.
119. Walczak, H.; Degli-Esposti, M. A.; Johnson, R. S.; Smolak, P. J.; Waugh, J. Y.; Boiani, N.; Timour, M. S.; Gerhart, M. J.; Schooley, K. A.; Smith, C. A.; Goodwin, R. G.; Rauch, C. T. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386-5397; 1997.
120. Degli-Esposti, M. A.; Smolak, P. J.; Walczak, H.; Waugh, J.; Huang, C.-P.; DuBose, R. F.; Goodwin, R. G.; Smith, C. A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1165-1170; 1997.
121. Chinnaiyan, A. M.; O'Rourke, K.; Yu, G.-L.; Lyons, R. H.; Garg, M.; Duan, D. R.; Xing, L.; Gentz, R.; Ni, J.; Dixit, V. M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274:990-992; 1996.
122. Bodmer, J.-L.; Burns, K.; Schneider, P.; Hofmann, K.; Steiner, V.; Thome, M.; Bornand, T.; Hahne, M.; Schröter, M.; Becker, K.; Wilson, A.; French, L. E.; Browning, J. L.; MacDonald, H. R.; Tschopp, J. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 6:79-88; 1997.
123. Marsters, S. A.; Sheridan, J. P.; Donahue, C. J.; Pitti, R. M.; Gray, C. L.; Goddard, A. D.; Bauer, K. D.; Ashkenazi, A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr. Biol. 6:1669-1676; 1996.
124. Kitson, J.; Raven, T.; Jiang, Y.-P.; Goeddel, D. V.; Giles, K. M.; Pun, K.-T.; Grinham, C. J.; Brown, R.; Farrow, S. N. A death-domain-containing receptor that mediates apoptosis. Nature 384:372-375; 1996.
125. Screaton, G. R.; Xu, X.-N.; Olsen, A. L.; Cowper, A. E.; Tan, R.; McMichael, A. J.; Bell, J. I. LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc. Natl. Acad. Sci. USA 94:4615-4619; 1997.
126. Marsters, S. A.; Sheridan, J. P.; Pitti, R. M.; Brush, J.; Goddard, A.; Ashkenazi, A. Identification of a ligand for the death-domain-containing receptor Apo3. Curr. Biol. 8:525-528; 1998.
127. Marsters, S. A.; Pitti, R. M.; Donahue, C. J.; Ruppert, S.; Bauer, K. D.; Ashkenazi, A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6:750-752; 1996.
128. Schneider, P.; Thome, M.; Burns, K.; Bodmer, J.-L.; Hofmann, K.; Kataoka, T.; Holler, N.; Tschopp, J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7:831-836; 1997.
129. Chaudhary, P. M.; Eby, M.; Jasmin, A.; Bookwalter, J.; Murray, J.; Hood, L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7:821-830; 1997.
130. Wajant, H.; Johannes, F.-J.; Haas, E.; Siemienski, K.; Schwenzer, R.; Schubert, G.; Weiss, T.; Grell, M.; Scheurich, P. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr. Biol. 8:113-116; 1998.
131. Kelliher, M. A.; Grimm, S.; Ishida, Y.; Kuo, F.; Stanger, B. Z.; Leder, P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8:297-303; 1998.
132. Yeh, W.-C.; Shahinian, A.; Speiser, D.; Kraunus, J.; Billia, F.; Wakeham, A.; de la Pompa, J. L.; Ferrick, D.; Hum, B.; Iscove, N.; Ohashi, P.; Rothe, M.; Goeddel, D. V.; Mak, T. W. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-725; 1997.
133. Lee, S. Y.; Reichlin, A.; Santana, A.; Sokol, K. A.; Nussenzweig, M. C.; Choi, Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713; 1997.
134. Watanabe-Fukunaga, R.; Brannan, C. I.; Copeland, N. G.; Jenkins, N. A.; Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317; 1992.
135. Takahashi, T.; Tanaka, M.; Brannan, C. I.; Jenkins, N. A.; Copeland, N. G.; Suda, T.; Nagata, S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976; 1994.
136. Lynch, D. H.; Watson, M. L.; Alderson, M. R.; Baum, P. R.; Miller, R. E.; Tough, T.; Gibson, M.; Davis-smith, T.; Smith, C. A.; Hunter, K.; Bhat, D.; Din, W.; Goodwin, R. G.; Seidin, M. F. The mouse fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131-136; 1994.
137. Rieux-Laucat, F.; Le Deist, F.; Hivroz, C.; Roberts, I. A. G.; Debatin, K. M.; Fischer, A.; de Villartay, J. P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349; 1995.
138. Fisher, G. H.; Rosenberg, F. J.; Straus, S. E.; Dale, J. K.; Middelton, L. A.; Lin, A. Y.; Strober, W.; Lenardo, M. J.; Puck, J. M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-946; 1995.
139. Tamiya, S.; Etoh, K.; Suzushima, H.; Takatsuki, K.; Matsuoka, M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 91:3935-3942; 1998.
140. Beltinger, C.; Kurz, E.; Böhler, T.; Schrappe, M.; Ludwig, W. D.; Debatin, K. M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 91:3943-3951; 1998.
141. Peng, S. L.; Robert, M. E.; Hayday, A. C.; Craft, J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184:1149-1154; 1996.
142. Davidson, W. F.; Giese, T.; Fredrickson, T. N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187:1825-1838; 1998.
143. Zörnig, M.; Grzeschiczek, A.; Kowalski, M.-B.; Hartmann, K.U.; Möröy, T. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in Eμ L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10:2397-2401; 1995.
144. Owen-Schaub, L. B.; van Golen, K. L.; Hill, L. L.; Price, J. E. Fas and fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 188:1717-1723; 1998.
145. Hahne, M.; Rimoldi, D.; Schröter, M.; Romero, P.; Schreier, M.; French, L. E.; Schneider, P.; Bornand, T.; Fontana, A.; Lienard, D.; Cerottini, J.-C.; Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363-1366; 1996.
146. Strand, S.; Hofmann, W. J.; Hug, H.; Müller, M.; Otto, G.; Strand, D.; Mariani, S. M.; Stremmel, W.; Krammer, P. H.; Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366; 1996.
147. Villunger, A.; Egle, A.; Marschitz, I.; Kos, M.; Böck, G.; Ludwig, H.; Geley, S.; Kofler, R.; Greil, R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 90:12-20; 1997.
148. Pitti, R. M.; Marsters, S. A.; Lawrence, D. A.; Roy, M.; Kischkel, F. C.; Dowd, P.; Huang, A.; Donahue, C. J.; Sherwood, S. W.; Baldwin, D. T.; Godowski, P. J.; Wood, W. I.; Gurney, A. L.; Hillan, K. J.; Cohen, R. L.; Goddard, A. D.; Botstein, D.; Ashkenazi, A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703; 1998.
149. Smets, L. A. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs 5:3-9; 1994.
150. Spadari, S.; Pedrali-Noy, G.; Focher, F.; Montecucco, A.; Bordoni, T.; Geroni, C.; Giuliani, F. C.; Ventrella, G.; Arcamone, F.; Ciarrocchi, G. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs. Anticancer Res. 6:935-940; 1986.
151. Dighiero, G. Potential immunological action of purine nucleoside analogues. Drugs 47(Suppl. 6):57-62; 1994.
152. Friesen, C.; Herr, I.; Krammer, P. H.; Debatin, K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-577; 1996.
153. Fulda, S.; Sieverts, H.; Friesen, C.; Herr, I.; Debatin, K.-M. The CD95 (APO-1/Fas) system mediates drug-induced apoplosis in neuroblastoma cells. Cancer Res. 57:3823-3829; 1997.
154. Muller, M.; Strand, S.; Hug, H.; Heinemann, E. M.; Walczak, H.; Hofmann,
155. Herr, I.; Wilhelm, D.; Böhler, T.; Angel, P.; Debatin, K.-M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16:6200-6208; 1997.
156. Hug, H.; Strand, S.; Grambihler, A.; Galle, J.; Hack, V.; Stremmel, W.; Krammer, P. H.; Galle, P. R. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. Biol. Chem. 272:28191-28193; 1997.
157. Faris, M.; Kokot, N.; Latinis, K.; Kasibhatla, S.; Green, D. R.; Koretzky, G. A.; Nel, A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol. 160:134-144; 1998.
158. Kasibhatla, S.; Brunner, T.; Genestier, L.; Echeverri,-F.; Mah-boubi, A.; Green, D. R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell 1:543-551; 1998.
159. Faris, M.; Latinis, K. M.; Kempiak, S. J.; Koretzky, G. A.; Nel, A. Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol. Cell. Biol. 18:5414-5424; 1998.
160. Los, M.; Herr, I.; Friesen, C.; Fulda, S.; Schulze-Osthoff, K.; Debatin, K.-M. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90:3118-3129; 1997.
161. Müller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S. L.; Galle, P. R.; Stremmel, W.; Oren, M.; Krammer, P. H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188:2033-2045; 1998.
162. Sheard, M. A.; Vojtesek, B.; Janakova, L.; Kovarik, J.; Zaloudik, J. Up-regulation of Fas (CD95) in human p53(wild-type) cancer cells treated with ionizing radiation. Int. J. Cancer 73:757-762; 1997.
163. Eischen, C. M.; Kottke, T. J.; Martins, L. M.; Basi, G. S.; Tung, J. S.; Earnshaw, W. C.; Leibson, P. J.; Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells - chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935-943; 1997.
164. Villunger, A.; Egle, A.; Kos, M.; Hartmann, B. L.; Geley, S.; Kofler, R.; Grell, R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:3331-3334; 1997.
165. Fuchs, E. J.; McKenna, K. A.; Bedi, A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res. 57:2550-2554; 1997.
166. Kataoka, T.; Schroter, M.; Hahne, M.; Schneider, P.; Irmler, M.; Thome, M.; Froelich, C. J.; Tschopp, J. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol. 161:3936-3942; 1998.
167. Gamen, S.; Anel, A.; Lasierra, P.; Alava, M. A.; Martinez-Lorenzo, M. J.; Pineiro, A.; Naval, J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett. 417:360-364; 1997.
168. McGahon, A. J.; Costa Pereira, A. P.; Daly, L.; Cotter, T. G. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br. J. Haematol. 101:539-547; 1998.
169. Fiedler, P.; Schaetzlein, C. E.; Eibel, H. Constitutive expression of Fas ligand in thyrocytes. Science 279; 1998: http://www.sciencemag.org/content/vol279/issue5359/
170. Stokes, T. A.; Rymaszewski, M.; Arscott, P. L.; Wang, S. H.; Bretz, J. D.; Bartron, J.; Baker, J. R. J. Constitutive expression of Fas ligand in thyrocytes. Science 279; 1998: http://www.sciencemag.org/content/vol279/issue5359/
171. Smith, D.; Sieg, S.; Kaplan, D. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J. Immunol. 160:4159-44160; 1998.
172. Reinke, V.; Lozano, G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15:1527-1534; 1997.
173. Wang, Y.; Szekely, L.; Okan, I.; Klein, G.; Wiman, K. G. Wild-type p53-triggered apoptosis is inhibited by bd-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431; 1993.
174. Ferrari, D.; Stepczynska, A.; Los, M.; Wesselborg, S.; Schulze-Osthoff, K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J. Exp. Med. 188:979-984; 1998.
175. Fulda, S.; Susin, S. A.; Kroemer, G.; Debatin, K.-M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 58:4453-1460; 1998.
176. Kondo, S.; Barna, B. P.; Morimura, T.; Takeuchi, J.; Yuan, J.; Akbasak, A.; Barnett, G. H. Interleukin-1 β-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55:6166-6171; 1995.
177. Adjei, P. N.; Kaufmann, S. H.; Leung, W. Y.; Mao, F.; Gores, G. J. Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate cysteine protease P32. J. Clin. Invest. 98:2588-2596; 1996. [Published erratum appears in J. Clin. Invest. 100(4):951; 1997]
178. Lotem, J.; Sachs, L. Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis. Proc. Natl. Acad. Sci. USA 94:9349-9353; 1997.
179. Los, M.; Van de Craen, M.; Penning, L. C.; Schenk, H.; Westendorp, M.; Baeuerle, P. A.; Droge, W.; Krammer, P. H.; Fiers, W.; Schulze-Osthoff, K. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375:81-83; 1995.
180. Enari, M.; Hug, H.; Nagata, S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81; 1995.
181. Tewari, M.; Dixit, V. M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270:3255-3260; 1995.
182. Turner, P. C.; Moyer, R. W. Control of apoptosis by poxviruses. Semin. Virol. 8:453-469; 1998.
183. Datta, R.; Banach, D.; Kojima, H.; Talanian, R. V.; Alnemri, E. S.; Wong, W. W.; Kufe, D. W. Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936-1943; 1996.
184. Bump, N. J.; Hackett, M.; Hugunin, M.; Seshagiri, S.; Brady, K.; Chen, P.; Ferenz, C.; Franklin, S.; Ghayur, T.; Li, P.; Licari, P.; Mankovich, J.; Shi, L.; Greenberg, A. H.; Miller, L. K.; Wong, W. W. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 269:1885-1888; 1995.
185. Izquierdo, M.; Grandien, A.; Criado, L. M.; Robles, S.; Leonardo, E.; Albar, J. P.; Gonzalez de Buitrago, G.; Martínez-A, C. Blocked negative selection of developing T cells in mice expressing the baculovirus p35 caspase inhibitor. EMBO J. 18:156-166; 1999.
186. Kuida, K.; Lippke, J. A.; Ku, G.; Harding, M. W.; Livingston, D. J.; Su, M. S.-S.; Flavell, R. A. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 267:2000-2003; 1995.
187. Li, P.; Allen, H.; Banerjee, S.; Franklin, S.; Herzog, L.; Johnston, C.; McDowell, J.; Paskind, M.; Rodman, L.; Salfeld, J.; Towne, E.; Tracey, D.; Wardwell, S.; Wei, F.-Y.; Wong, W.; Kamen, R.; Seshadri, T. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80:401-4111; 1995.
188. Smith, D. J.; McGuire, M. J.; Tocci, M. J.; Thiele, D. L. IL-1β Convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms. J. Immunol. 158:163-170; 1997.
189. Boehme, S. A.; Lenardo, M. J. TCR-mediated death of mature T lymphocytes occurs in the absence of p53. J. Immunol. 156:4075-41078; 1996.